Pliant Therapeutics Inc (PLRX) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target
Pliant Therapeutics Inc stock (PLRX) is currently trading at $1.28. Pliant Therapeutics Inc PS ratio (Price-to-Sales) is 3071.82. Analyst consensus price target for PLRX is $2.67. WallStSmart rates PLRX as Sell.
- PLRX PE ratio analysis and historical PE chart
- PLRX PS ratio (Price-to-Sales) history and trend
- PLRX intrinsic value — DCF, Graham Number, EPV models
- PLRX stock price prediction 2025 2026 2027 2028 2029 2030
- PLRX fair value vs current price
- PLRX insider transactions and insider buying
- Is PLRX undervalued or overvalued?
- Pliant Therapeutics Inc financial analysis — revenue, earnings, cash flow
- PLRX Piotroski F-Score and Altman Z-Score
- PLRX analyst price target and Smart Rating
Pliant Therapeutics Inc
📊 No data available
Try selecting a different time range
Smart Analysis
Pliant Therapeutics Inc (PLRX) · 6 metrics scored
Smart Score
Category Performance
WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.
Investment Thesis
Strong fundamentals in price/book, institutional own.. Concerns around market cap and return on equity. Significant fundamental concerns warrant caution or avoidance.
Pliant Therapeutics Inc (PLRX) Key Strengths (2)
Trading below book value, meaning the market prices it less than net assets
77.72% of shares held by major funds and institutions
Supporting Valuation Data
Pliant Therapeutics Inc (PLRX) Areas to Watch (4)
Company is destroying shareholder value
Revenue declining -100.00%, a shrinking business
Very expensive at 3071.8x annual revenue
Micro-cap company with very limited liquidity and high volatility
Supporting Valuation Data
Pliant Therapeutics Inc (PLRX) Detailed Analysis Report
Overall Assessment
This company scores 25/100 in our Smart Analysis, earning a F grade. Out of 6 metrics analyzed, 2 register as strengths (avg 10.0/10) while 4 fall into concern territory (avg 1.3/10). The category breakdown reveals uneven performance, with some areas requiring attention.
The Bull Case
The strongest argument centers on Price/Book, Institutional Own.. Valuation metrics including Price/Book (0.44) suggest the stock is attractively priced.
The Bear Case
The primary concerns are Return on Equity, Revenue Growth, Price/Sales. Some valuation metrics including Price/Sales (3071.82) suggest expensive pricing. Growth concerns include Revenue Growth at -100.00%, which may limit upside. Profitability pressure is visible in Return on Equity at -61.60%.
Key Dynamics to Monitor
Three factors to monitor going forward. First, whether Return on Equity improves, as this is the primary drag on the overall score. Second, margin trajectory, with Return on Equity at -61.60% needing improvement to support the investment thesis. Third, growth sustainability, with Revenue Growth at -100.00% needing to reaccelerate.
Risk Considerations
Based on the metric profile, this is a higher risk investment. There are more areas of concern than strength, warranting a more conservative position size. Investors should size positions according to their risk tolerance and maintain diversification.
Bottom Line
Fundamental challenges outweigh strengths at current levels. Return on Equity and Revenue Growth are the primary drags. Consider waiting for meaningful improvement before committing capital.
Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.
PLRX Price-to-Sales(PS) Ratio Chart
Historical valuation based on market cap ÷ trailing 12-month revenue
PLRX's Price-to-Sales ratio of 3071.82x trades 612% above its historical average of 431.28x (91th percentile), historically expensive. The current valuation is 0% below its historical high of 3071.82x set in Mar 2026, and 14328% above its historical low of 21.29x in Nov 2021. Over the past 12 months, the PS ratio has expanded from ~57.2x, reflecting growing market expectations outpacing revenue growth.
WallStSmart Analysis Synopsis
Data-driven financial summary for Pliant Therapeutics Inc (PLRX) · HEALTHCARE › BIOTECHNOLOGY
The Big Picture
Pliant Therapeutics Inc operates as a stable business with moderate growth and solid fundamentals.
Key Findings
Revenue contracted 100% YoY. Worth determining whether this is cyclical or structural.
Free cash flow is -18M, meaning the company is burning cash. This may be acceptable for high-growth companies investing heavily.
What to Watch Next
Sector dynamics: monitor BIOTECHNOLOGY industry trends, competitive moves, and regulatory changes that could impact Pliant Therapeutics Inc.
Bottom Line
Pliant Therapeutics Inc offers stability with moderate growth and solid fundamentals. The valuation may present an opportunity for patient investors, though limited growth means returns will likely come from dividends and modest capital appreciation rather than explosive gains.
This synopsis is generated from publicly available financial data. It is not financial advice. Always conduct your own research and consult a qualified financial advisor before making investment decisions.
Insider Transactions(8 last 3 months)
Data sourced from SEC Form 4 filings
Last updated: 10:04:38 AM
About Pliant Therapeutics Inc(PLRX)
NASDAQ
HEALTHCARE
BIOTECHNOLOGY
USA
Pliant Therapeutics, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and markets new therapies for the treatment of fibrosis and related diseases in the United States. The company is headquartered in South San Francisco, California.